14-16. Reduce invasive early onset group B streptococcal disease.

National Data Source Active Bacterial Core Surveillance (ABCs), CDC,

NCIRD.

State Data Source Not identified.

Healthy People 2000

Objective

Not applicable.

Changes since the

2000 Publication

None.

Measure Rate per 1,000 live births.

Baseline (Year) 1.0 (1996)

Target 0.5

Target-Setting Method Better than the best racial/ethnic subgroup.

For a discussion of target-setting methods, see Part

A, section 4.

Numerator Number of newborns aged 0 to 6 days with a newly

reported laboratory-confirmed case of early-onset

group B streptococcal disease.

Denominator Number of live births.

Population Targeted Resident population (selected regions in eight

States) (see Comments).

Questions Used To

Obtain the National

Baseline Data

CDC Active Surveillance Bacterial Meningitis and

Bacteremia Case Report, Form 52.15A.

Expected Periodicity Annual.

Comments A laboratory-confirmed case of group B

Streptococcus is defined as either the isolation of group B Streptococcus from cerebrospinal fluid or a positive culture of group B Streptococcus from a different normally sterile site (blood, pleural fluid,

etc.) in a newborn aged 0 to 6 days in the

surveillance area.

ABCs is an active and laboratory-based case surveillance system. Data are collected from acute care hospitals and reference laboratories for laboratory-confirmed cases as well as from case report forms.

Data are based on surveillance of selected regions in eight States: California, Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee.

More information on laboratory-based surveillance for meningococcal disease (including group B streptococcal disease) is provided by CDC.¹

See Appendix A for focus area contact information.

References

1. CDC. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-91. *Morbidity and Mortality Weekly Report* 42 (SS-2).

Operational Definition: Objective 14-16